In November, we observe Crohn's & Colitis Awareness Month. Alimentiv is dedicated to advancing the well-being of those living with Crohn's disease and ulcerative colitis through our unwavering commitment to research. Alimentiv's Precision Medicine team is devoted to enhancing patient care by investing in translational research and cutting-edge technologies. We strive to pinpoint cell and tissue biomarkers that can be leveraged to customize therapies, ensuring the right patient receives the right drug at the right time. Understanding the unique effectiveness of drug therapies in different individuals is key. To bridge these gaps and elevate our approach to Crohn's disease and ulcerative colitis treatment, a comprehensive understanding of disease biology and drug mechanisms is essential. Learn More: https://bit.ly/3SwWeQK #CrohnsAndColitisAwarenessMonth #CrohnsAndColitis #Crohns #Colitis #IBD
Alimentiv’s Post
More Relevant Posts
-
Excited to share that Alimentiv will be presenting four posters at #UEGWeek in Vienna! Our research highlights include an interim analysis of the VERDICT trial, a collaboration with Takeda exploring optimal treatment targets for ulcerative colitis. Stop by booth #57 to learn about our latest innovations in GI research, including updates on the VERDICT trial for ulcerative colitis. Read more here: https://bit.ly/3A7mVV7 #Alimentiv #ClinicalTrials #Innovation #Research
-
-
🌟 Join Alimentiv at UEG Week! We're excited to be exhibiting four poster presentations at the United European Gastroenterology (UEG) conference in Vienna, Austria from October 12-15. Don’t miss the latest research results from Alimentiv’s medical experts featuring Dr. Vipul Jairath, Dr. Virginia Solitano, and Dr. Angelica Rivas. https://lnkd.in/gmZ8KE7m Come visit us at booth #57 to learn more about our research and end-to-end GI clinical trial services. We look forward to seeing you there! Book a meeting with us https://lnkd.in/g27mbTn8 #UEGWeek #Alimentiv #GI
-
📣 New study alert! A new study in Med by Cell Press, led by Virginia Solitano and Christopher Ma, compared the responsiveness of various #UlcerativeColitis (UC) activity indices in patients with moderately to severely active UC treated with ustekinumab. The study highlights the importance of selecting the right disease activity index based on the evaluation setting and treatment goals. Read more Alimentiv publications here: https://lnkd.in/gXmuRe-F #Alimentiv #IBD #ulcerativecolitis #clinicaltrials #clinicalresearch
A new study in Med by Cell Press compared the responsiveness of various ulcerative colitis (UC) activity indices in patients with moderately to severely active UC treated with ustekinumab https://lnkd.in/eCSTgdmW The Mayo Clinic score (MCS), modified MCS (mMS), partial MCS (pMS), Robart’s Histopathology Index (RHI), and UC-100 score were evaluated. The results showed that existing indices for measuring disease activity were similarly responsive to change after treatment. The mMS was found suitable as a composite endpoint, while the UC-100 score was more appropriate for settings involving histological evaluation. The study highlights the importance of selecting the appropriate disease activity index based on the evaluation setting and treatment goals. Virginia Solitano ∙ Remo Panaccione ∙ Bruce Sands ∙ Zhongya Wang ∙ Malcolm Hogan ∙ Guangyong Zou ∙ Laurent Peyrin-Biroulet ∙ Silvio Danese ∙ Linda Cornfield ∙ Brian G Feagan ∙ Siddharth Singh ∙ Vipul Jairath ∙ Christopher Ma Western University Alimentiv Libera Università Vita-Salute San Raffaele University of Calgary Icahn School of Medicine at Mount Sinai University Hospital of Nancy University of Lorraine IRCCS Ospedale San Raffaele UC San Diego #UlcerativeColitis #Ustekinumab #DiseaseActivityIndices
-
-
🗓️ Mark your calendar! Dr. Angelica Rivas, will be discussing evaluating placebo rates in eosinophilic esophagitis at this year’s UEG Week conference. Date & Time: October 14, 2024 4:00 PM – 5:00 PM EDT (UTC -4) See you there! #Alimentiv #EoE #ClinicalResearch
-
-
LATEST NEWS! VECTORS study first participants randomized in Crohn’s disease and transmural healing by using intestinal ultrasound (IUS). We're pleased to confirm the first participants have been randomized in the VECTORS study! VECTORS is a unique study in #CrohnsDisease (CD) research aiming to answer a key clinical question related to the optimal treatment algorithm to achieve a target of transmural healing in Crohn’s disease. VECTORS will also provide key insights into the use of intestinal ultrasound as a non-invasive modality in Crohn’s disease clinical trials and clinical practice. VECTORS is a collaborative study between Alimentiv and Takeda and a testament to the dedication of both organizations to improve the lives of patients living with IBD. Learn more: https://bit.ly/3zkz1tX #Alimentiv #IBD #Ultrasound #MedicalResearch #ClinicalTrials
-
-
At Alimentiv, we're not just a CRO – we lead with science and innovation in GI research. Our medical research and development experts, along with our KOL collaborators, are actively shaping the design and outcome of trials for IBD and GI-related diseases. Explore our exclusive #publication collection: https://bit.ly/3BnRIxe #Alimentiv #Gastroenterology #CRO #MedicalResearch #ClinicalTrials
-
Today in Canada, we mark the National Day for Truth and Reconciliation. Alimentiv stands with the children who never returned home, survivors of the residential schools, and their families and communities. Join us in wearing orange today. Let's reflect, learn, and acknowledge the past to create a better future together with our Indigenous communities. #NDTR #TruthAndReconciliation #OrangeShirtDay #EveryChildMatters
-
-
Join Dr. Virginia Solitano at the upcoming #UEGWeek where she will be presenting on “Interventions for the Management of Complications in Patients with Inflammatory Bowel Disease and Permanent Ileostomy for the Endotrial Consortium: A Systematic Review.” Date & time: October 14, 2024, from 11:30 AM to 12:30 PM EDT (UTC –4) #Alimentiv #IBD #ClinicalResearch
-
-
Join us at #UEGWeek where Dr. Vipul Jairath, Principal Investigator for the VERDICT study, will present data on target achievement in patients with moderate to severe ulcerative colitis participating in the VERDICT study, a trial focused on evaluating different algorithms of achieving treatment target in ulcerative colitis. Stop by booth #57 to learn more about our innovative research! #Alimentiv #IBD #ClinicalResearch
-
-
At Alimentiv, we believe that strong leadership is the cornerstone of a thriving organization. That's why we're thrilled to celebrate our leaders for completing Year 1 of the Olive Tree Alimentiv Leadership Development Program through the Ivey Academy! 🌱 A special thank you to Arti Ramji and The Ivey Academy at Ivey Business School team for crafting a program that truly reflects our core values and strategic vision. Here's to a future filled with growth, innovation, and exceptional leadership! #Alimentiv #LeadershipDevelopment #PeopleFocused
-
